A Phase 4 interventional study of Control group and DPP-4 inhibitor group in Cognitive Impairment, sponsored by Beni-Suef University. Not yet recruiting at 1 site in Egypt. Open to participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Beni-Suef University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing metformin in Cognitive Dysfunction — 3 open to participants now, 4 under way, 2 of them phase 3. Metformin · Cognitive Dysfunction.
Among the 10 studies testing metformin in Cognitive Dysfunction, this one is the 3rd largest by planned enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 9th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →3 of the 10 studies testing metformin in Cognitive Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 60–75
Donald Mabbott · Sites in Australia, Canada
Ages 7–21
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 45 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2 · Phase 4 3
First in 2008; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 84 across the 10 interventional studies. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
Beni-Suef University is the lead sponsor of 350 studies on the registry; 124 are open to participants now.
Beni-Suef University has 3 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
1 of the studies testing metformin in Cognitive Dysfunction that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05230758Phase 3Donald MabbottEffect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing metformin in Cognitive Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized controlled clinical trial with a parallel-group design conducted at Minia University hospital.
All patients admitted to Diabetes clinics of Minia University Hospital, will be screened for the eligibility criteria.
diabetic patients (aged above 50 years) with uncontrolled diabetes on oral hypoglycemic drugs. 105 patients will be enrolled and randomized into three groups.
Group I=35 T2DM patients given DPP4Is Group II=35 T2DM patients given DPP4Is and metformin. Group III=35 patients will be given placebo (only adjust their drugs to control blood glucose level)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type-2 diabetic adult subjects (above 50 years old) who had uncontrolled (A1c=8-9 %) blood glucose levels with an oral hypoglycemic drug at the screening visit were eligible to participate.
Exclusion Criteria:
Those with type1 diabetes or ketoacidosis, end organ failure as chronic renal failure (estimated serum creatinine level ≥ 1.5mg/dl in male and ≥ 1.4mg/dl in female), liver cell failure (elevated (ALT) and aspartate transaminase (AST) ≥ 2 folds), and heart failure, previous history of pancreatitis, and pregnant or lactating females were excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
35 patients will be given placebo (only adjust their drugs to control blood glucose level)
Drug: Control group
35 T2DM patients will be given DPP4Is once or twice daily
Drug: DPP-4 inhibitor group
35 T2DM patients will be given DPP4Is + metformin once or twice daily
Drug: DPP-4 inhibitor + metformin group
35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)
35 T2DM patients will be given DPP-4 I once or twice daily
Drug pages: DPP-4 inhibitorsStudies of DPP-4 inhibitorsDPP-4 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
35 T2DM patients will be given DPP-4 I + metformin once or twice daily
Serum Inflammatory mediators; TNF-α
ELISA kits
Time frame: Before and post 6 month of treatment
MMSE score
Validated questionnaire assessing the Estimation of Mini Mental State The MMSE has a maximum score of 30 points. The scores are generally grouped as follows: 25-30 points: normal cognition 21-24 points: mild dementia 10-20 points: moderate dementia Examination (MMSE) score
Time frame: Before and post 6 month of treatment
PHQ-9
Validated questionnaire assessing patient mental health and depression PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression.;
Time frame: Before and post 6 month of treatment
serum amyloid-β
Time frame: Before and post 6 month of treatment
Serum Insulin
ElISA kits
Time frame: Before and post 6 month of treatment
Serum fasting and 2-he post prandial glucose
Time frame: Before and post 6 month of treatment
HOMA-IR
Time frame: Before and post 6 month of treatment
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2023; primary completion for Jun 2024, 6 months later.
Of 43 non-industry phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 69. This study's planned 6 months is below that.
Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 20 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: DPP-4 inhibitors · Metformin